North Chicago-based drugmaker AbbVie has asked a federal judge to toss out a $140 million verdict against it for allegedly mismarketing its testosterone replacement therapy drug, Androgel. And in the view of a Chicago attorney whose practice focuses on Supreme Court and appellate cases, as well as class actions, there is "no chance" that judgment will be allowed to stand.
Label or Liability: Case law could lead to short shelf life for $3M Paxil 'innovator liability' verdict
A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability.
Federal judge tosses some accusations vs testosterone drug makers on eve of Androgel bellwether trials
A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline.
Consumers too far down distribution chain to press price fixing class action vs steelmakers, says judge
A group of steel makers, led by Chicago-based ArcelorMittal USA, have beaten down a class-action antitrust lawsuit filed by more than a dozen consumers, who alleged the companies schemed to raise prices for goods made with steel, by pointing out the consumers were too far down the distribution line from the steel manufacturers to claim losses.
A Chicago federal judge has chopped a few counts from a huge putative class-action suit – based on laws of various states, including Illinois – accusing the maker of the prescription pain killer Opana of improperly keeping the price of its product high by paying off another pharmaceutical company to delay the release of a generic version of the drug.
A Chicago federal judge has kicked drug retailers Walgreen and Rite Aid from an antitrust lawsuit against the maker of prescription pain killer Opana, saying the retailers must provide hard dollar figures to back up their allegations that the drugmaker improperly paid off another pharmaceutical company to delay the release of the generic version of its pain killer, and keep the price of its name brand drug high.